
Biogen downplays capacity for M&A; Roche’s SMA drug is approved as a tablet
Plus, news about Odyssey Therapeutics, GSK, Aligos Therapeutics, Terrain Biosciences, the Gates Foundation and Neuphoria Therapeutics:
Biogen appears to back away from dealmaking projections: The …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.